A Clinical Trial to Investigate Biomarker Effects of Pre-Surgical Treatment With DDR Agents in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC) Who Are Planned to Undergo Surgery That is Likely to be Followed by Radiotherapy and/or Chemotherapy

Trial Profile

A Clinical Trial to Investigate Biomarker Effects of Pre-Surgical Treatment With DDR Agents in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC) Who Are Planned to Undergo Surgery That is Likely to be Followed by Radiotherapy and/or Chemotherapy

Recruiting
Phase of Trial: Phase I

Latest Information Update: 09 Apr 2018

At a glance

  • Drugs AZD 6738 (Primary) ; Olaparib (Primary)
  • Indications Head and neck cancer; Squamous cell cancer
  • Focus Biomarker; Pharmacodynamics
  • Sponsors AstraZeneca
  • Most Recent Events

    • 03 Jan 2018 Planned End Date changed from 9 Oct 2019 to 3 Sep 2019.
    • 03 Jan 2018 Planned primary completion date changed from 9 Oct 2019 to 3 Sep 2019.
    • 28 Nov 2017 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top